Jump to any asset
850 assets, updated daily
As of September 12, 2026, Replimune Group, Inc. (REPL) trades at $12.92. CleaRank Financial AI rates it Sell with a fair value of $12.92, in line with the current price. Wall Street's consensus target is $19.50 across 8 analysts. RSI at 33 is in neutral territory, and the price is above its 50-day average of $12.45.
Replimune Group, Inc. (REPL)
Replimune Group, Inc. NASDAQ
$12.92
-0.3200 (-2.42%)
At close: Sep 11, 4:00 PM EDT
AI Analyst Consensus
21 / 100
Replimune Group, Inc. (REPL) is currently trading at $12.92, with its price above its 50-day and 200-day moving averages ($12.45 and $8.69) but below its 20-day EMA, indicating mixed short-term technical signals. The company has experienced significant insider selling totaling $2.6 million in the past 43 transactions, with no reported insider purchases. This net selling pressure, coupled with a negative EPS of -$3.15, raises concerns about the company's near-term financial health and investor confidence, despite a generally positive sentiment from Wall Street analysts.
REPL Price Analysis
Market Metrics
Open
$13.33
Day Range
$12.40 to $13.74
Prev Close
$13.24
Volume
4.08M
52-Week Range
$1.50 to $16.33
Market Cap
$1.22B
Peer Benchmarking
Valuation vs Sector (Healthcare)
Performance vs XLV
Sector Position Analysis
REPL Financial Performance
Revenue vs. Earnings
Annual
Quarterly
Earnings Reality Check
Analysis: In the last 5 quarters, REPL beat estimates 4 times. However, the stock fell 3 times the next day. This suggests positive news is often "priced in" or investors are selling the news.
REPL Analysis
Company's Health
2/5
AI Technical Analysis
Replimune Group, Inc. (REPL) is trading above its 50-day and 200-day moving averages ($12.45 and $8.69), suggesting a longer-term bullish trend. However, the stock is currently below its 20-day exponential moving average, indicating some short-term weakness. The Relative Strength Index (RSI) is at 33.33, signaling bearish momentum. Volume has been notably high, with the latest volume at 4,084,167, more than double the average volume of 2,041,557, suggesting significant investor interest and potential for volatility.
ProTips
- Monitor insider transactions closely; the recent $2.6 million in net selling by insiders warrants significant attention and could signal a lack of confidence.
- The RSI is currently below 50, indicating bearish momentum. Investors should watch for a potential bounce if the RSI moves back above 50, but the current trend is negative.
- Given the negative EPS and mixed earnings performance, investors should consider the company's cash burn rate and long-term funding strategy.
Key Catalysts
Bearish
Significant Insider Selling
Insiders have sold $2.6 million worth of stock across 43 transactions, with no reported insider purchases, indicating a potential lack of confidence in future performance.
Source: Insider TransactionsBearish
Negative EPS Trend
Replimune Group, Inc. has a current EPS of -$3.15, and recent earnings reports show inconsistent performance with a persistent negative EPS trend, raising concerns about profitability.
Source: Earnings ReportsBullish
Positive Analyst Sentiment
The majority of Wall Street analysts maintain a 'Buy' rating, with a median price target of $19.50, suggesting an expected upside of 50.9% from the current price.
Source: Wall Street AnalystsBullish
Strong Forward Revenue Growth Projection
Next year's revenue estimates show a projected growth of 490.00% to $50.2 million, indicating significant potential for future top-line expansion.
Source: Revenue EstimatesMarket Outlook
The outlook for Replimune Group, Inc. (REPL) is cautiously bearish, primarily due to significant insider selling and a negative EPS. While Wall Street analysts maintain a 'Buy' consensus with a median price target of $19.50, the current price action and insider activity suggest potential headwinds. The company's forward revenue estimates show strong projected growth, but this must be weighed against the current profitability challenges and the signal from insider transactions.
Key Statistics
| Market Cap | 1.22B |
|---|---|
| P/E Ratio | N/A (Negative EPS) |
| EPS (TTM) | -3.15 |
| Dividend Yield | 0.00% |
| 52 Week High | 16.33 |
| 52 Week Low | 1.50 |
Replimune Group, Inc. (REPL) exhibits a negative EPS of -$3.15, making traditional P/E ratio analysis inapplicable. The company's revenue growth is not provided, but forward revenue estimates for next year show a substantial projected increase of 490.00% to $50.2 million, albeit with a capped average that suggests potential outlier skew. The current price of $12.92 is below the median Wall Street price target of $19.50, implying a potential upside of 50.9%, but this is contrasted by significant insider selling.
Earnings & Growth Analysis
Replimune Group, Inc. (REPL) most recently reported an EPS of -$0.72, beating the estimated -$0.77 by 6.49%, though the stock saw a -2.27% price change. Prior to this, the company missed estimates in the June 2026 quarter. The March 2026 quarter showed a significant EPS beat of 11.86%, but the stock price reacted negatively. Overall, earnings performance has been inconsistent, with a mix of beats and misses, and a persistent negative EPS trend.
Key Risks
The primary risk for Replimune Group, Inc. (REPL) stems from significant insider selling totaling $2.6 million, indicating a lack of confidence from management. The company also carries a negative EPS of -$3.15, raising concerns about its profitability and financial sustainability. While Wall Street maintains a 'Buy' consensus, the bearish technical momentum and insider activity present considerable downside risks.
Technical Indicators
| RSI (14) | 33.33 |
|---|---|
| MACD | 0.41 |
| SMA 50 | 12.45 |
| SMA 200 | 8.69 |
RSI
Bearish
SMA Cross
Bullish
Price vs SMA
Bullish
MACD
Bullish
Golden Cross in effect with the 50-day SMA ($12.45) above the 200-day SMA ($8.692), price action is firmly bullish above key moving averages.
Market Correlations
How this stock moves relative to other assets
Based on 1 year of daily price data. Correlations may vary over different time periods.
S&P 500 (SPY)
+0.03
Weak correlation
Nasdaq 100 (QQQ)
+0.05
Weak correlation
Bitcoin (BTC)
-0.05
Weak correlation
Gold (XAU)
+0.02
Weak correlation
Check Custom Correlation
Calculating correlation...
REPL Trade Plans
Specific entry, exit, and risk management levels
Select Your Trade Bias
Risk Tolerance
Conservative
2%
Aggressive
Portfolio Value
$
Position Size: Enter portfolio size →
🔴 SHORT ENTRY (click to switch)
CONSERVATIVE
$13.18
2% above current price
Lower risk, wait for rally
AGGRESSIVE
$12.92
Short at current price
Higher risk, chasing the move
Risk Management
STOP LOSS
$15.31
MAX LOSS
-16.2%
Volatility-Adjusted Stop Loss
Calculated based on RSI (33.3) and current market volatility
Profit Targets (Based on Conservative Entry)
TARGET 1
$12.52
-5% (Conservative)
-3.1% (Aggressive)
TARGET 2
$11.86
-10% (Conservative)
-8.2% (Aggressive)
TARGET 3
$11.20
-15% (Conservative)
-13.3% (Aggressive)
Consider scaling out: Take 50% profit at Target 1, 30% at Target 2, let 20% run to Target 3
Calculate Your Trade
High-Volatility Risk Disclaimer
REPL is classified as a high-volatility asset (Daily Vol: 5.12%). Aggressive price swings can lead to rapid capital loss. Liquidity risks may prevent exiting trades at desired prices. This AI-generated analysis is for educational purposes only and is not financial advice. Generated on September 12, 2026.Growth of $10,000
A $10,000 investment in REPL in July 2018 would be worth about $8,522 today, compared with about $27,327 for the same investment in the S&P 500 benchmark.
Compare with Another Ticker
Monte Carlo Projection (10yr)
CleaRank's 10-year Monte Carlo simulation projects that a $10,000 investment in REPL today could grow to about $12,218 by 2036 in the base case, with a bull case near $92,695 and a bear case around $1,610. Projections are statistical simulations, not guarantees.
REPL Stock Price Prediction: 2030
CleaRank's simulation projects a price near $14.00 for REPL by 2030 in the base case, from $12.92 today (1.1x over 4 years). The downside path ends near $3.89. These are outcomes of a Monte Carlo simulation run on REPL's historical return distribution, not price targets, and they assume no dividends are reinvested.
| Year | Downside (10th pct) | Base case | Upside (90th pct) |
|---|---|---|---|
| 2027 | $6.94 | $13.18 | $25.02 |
| 2028 | $5.43 | $13.45 | $33.28 |
| 2029 | $4.52 | $13.72 | $41.63 |
| 2030 | $3.89 | $14.00 | $50.43 |
| 2031 | $3.41 | $14.28 | $59.85 |
| 2032 | $3.03 | $14.57 | $70.01 |
| 2033 | $2.73 | $14.87 | $81.00 |
| 2034 | $2.48 | $15.17 | $92.90 |
| 2035 | $2.26 | $15.47 | $106 |
| 2036 | $2.08 | $15.79 | $120 |
Method: 10,000 simulated price paths using REPL's historical volatility and drift, re-run daily. The base case is the median path; the two outer columns are the 10th and 90th percentile outcomes, which widen with time because uncertainty compounds. Simulations are not guarantees, and past volatility does not predict future returns. This is analysis, not investment advice.
People Also Watch
REPL Insider Trading Analysis
Bought
None
No open-market buys
Sold
$2.6M
24 Transactions
Insiders
7
Active Traders
Avg Transaction
$107.7K
Moderate size
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| Dec 9, 2020 | RHODES JASON P
Director
|
Sell | 217.4K | $10.0M |
| Dec 22, 2020 | COFFIN ROBERT
President
|
Sell | 220.0K | $8.8M |
| Dec 14, 2020 | RHODES JASON P
Director
|
Sell | 103.7K | $4.5M |
| Jul 9, 2020 | COFFIN ROBERT
President
|
Sell | 169.8K | $3.8M |
| Sep 17, 2021 | OMEGA FUND IV, LP.
Beneficial Owner of more than 10% of a Class of Security
|
Sell | 100.0K | $3.3M |
| Dec 17, 2020 | RHODES JASON P
Director
|
Sell | 65.0K | $2.7M |
| Jan 22, 2021 | COFFIN ROBERT
President
|
Sell | 60.0K | $2.7M |
| Jan 19, 2021 | ESPOSITO PAMELA
Officer
|
Sell | 55.0K | $2.4M |
| Jan 19, 2021 | ESPOSITO PAMELA
Officer
|
Sell | 55.0K | $2.4M |
| Jan 19, 2021 | ASTLEY-SPARKE PHILIP
Chief Executive Officer
|
Sell | 50.0K | $2.2M |
Page 1 of 1
Frequently Asked Questions
What is Replimune Group, Inc.'s current stock price and outlook?
Replimune Group, Inc. (REPL) is currently trading at $12.92. The outlook is mixed, with a 'Buy' consensus from Wall Street analysts and a median price target of $19.50, but tempered by significant insider selling and bearish technical momentum.
Is Replimune Group, Inc. stock a buy or sell?
Based on the current data, the consensus rating is 'Sell' with a score of 18. While Wall Street analysts largely rate it a 'Buy', significant insider selling and negative EPS trends suggest caution.
What are the key risks facing Replimune Group, Inc.?
The primary risks include substantial insider selling totaling $2.6 million, a negative EPS of -$3.15, and bearish momentum indicated by the RSI. These factors outweigh the positive sentiment from Wall Street analysts.
How has Replimune Group, Inc. performed in recent earnings reports?
Replimune Group, Inc. (REPL) recently beat EPS estimates by 6.49% in its latest report, but the stock price declined. Prior quarters have shown inconsistent performance with both beats and misses, and a persistent negative EPS trend.
What is the technical outlook for Replimune Group, Inc. stock?
Technically, REPL is trading above its 50-day and 200-day moving averages ($12.45 and $8.69) but below its 20-day EMA. The RSI is in bearish territory at 33.33, indicating bearish momentum, despite the longer-term moving average support.
What is Replimune Group, Inc.'s revenue growth projection?
However, forward estimates for next year project significant growth of 490.00% to $50.2 million, though this average may be skewed by outliers.
What is Replimune Group, Inc.'s stock forecast for 2030?
According to Monte Carlo simulations, Replimune Group, Inc.'s stock forecast for 2030 shows a base case price of $14, with a downside projection of $3.89 and an upside projection of $50.43. These are simulation outcomes, not guarantees.